Retrograde intrarenal surgery with flexible and navigable suction ureteral access sheaths vs. percutaneous nephrolithotomy for 2–3 cm kidney stones: Is less ınvasive better?

Creative Commons License

Degirmentepe R. B., Akca Y. M., Alp S., Cimen H. I., Gul D., Erkoc M., ...Daha Fazla

Canadian Urological Association Journal, cilt.20, sa.1, 2025 (SCI-Expanded, Scopus)

Özet

Introduction: The management of renal stones measuring 2–3 cm remains a clinical challenge, with percutaneous nephrolithotomy (PCNL) traditionally favored over retrograde intrarenal surgery (RIRS) due to higher stone-free rates (SFR); however, advancements in flexible ureteroscopy and the introduction of flexible and navigable suction ureteral access sheaths (FANS-UAS) have expanded the role of RIRS for larger stones. This study compares the efficacy and safety of PCNL vs. FANS-UAS-assisted RIRS for medium-sized renal calculi. Methods: This retrospective study included 116 patients (50 RIRS, 66 PCNL) with 2–3 cm renal stones treated at a single institution. RIRS was performed using an 11/13 Fr FANS-UAS, while PCNL followed standard techniques. Outcomes assessed included operative time, hospitalization, hemoglobin drop, SFR (defined as no fragments ≥1 mm on three-month computed tomography), and complications (Clavien-Dindo). Results: Baseline characteristics were comparable between groups (p>0.05). RIRS demonstrated significantly shorter operative times (63.1±11.3 vs. 97.3±15.1 minutes, p<0.001) and hospitalization (28.3±17.9 vs. 81±24.8 hours, p<0.001), with less hemoglobin drop (0.4±0.5 vs. 2.1±1.7 g/dL, p<0.001). SFRs were similar at three months (70% RIRS vs. 74.2% PCNL, p=0.677). PCNL had higher complication rates, including three grade III events (vs. none in RIRS), although not statistically significant (p=0.277). Conclusions: FANS-UAS-assisted RIRS offers comparable SFRs to PCNL for 2–3 cm stones, with advantages in operative efficiency, hospitalization, and perioperative safety. These findings suggest RIRS as a viable minimally invasive alternative, warranting further randomized trials to validate its role in this setting.